经FDA批准并由医生监督

GLP-1 医疗减重计划

多年来一直在为减肥而苦恼吗?
获得医生处方的解决方案,通过调节食欲并解决荷尔蒙和代谢因素,支持可持续减重。

30 min

Wait before food or drink (3)

120 ml

Most water to take it with (3)

14 mg

Highest daily diabetes dose (3)

💡

A note on terminology

This page uses semaglutide, the generic name, for both the daily tablet and the weekly injection, in line with Singapore's medical advertising guidelines, which restrict reference to registered trade names.

Where the semaglutide tablet stands today

The tablet and the injection share an active ingredient but not a registered use. It is worth being clear on the difference before you see a doctor.

✓ 2019 — First GLP-1 tablet approved. US regulators approved oral semaglutide for adults with type 2 diabetes, the first GLP-1 medicine available as a tablet. (1)

✓ Singapore — Registered for type 2 diabetes. Here, the tablet is registered to improve blood sugar control in adults with type 2 diabetes, alongside diet and exercise. (5)

✓ Late 2025 — Higher-strength tablet approved overseas for weight. US regulators approved a 25 mg daily semaglutide tablet for chronic weight management, based on the OASIS trials. It is a different product from the diabetes tablet. (4)

▸ Weight management — Not registered in Singapore. The diabetes tablet is not registered here for weight loss. Using it for weight alone would be off-label, and is a decision for a doctor after a full assessment. (5)

Why the tablet needs a strict routine

Semaglutide is a peptide, a small protein that stomach acid normally breaks down. Swallowed on its own, almost none of it would reach the bloodstream.

The tablet contains an absorption enhancer called SNAC, which briefly protects semaglutide and helps it cross the stomach lining. That protection only lasts a short time, and food, drinks or other tablets easily disrupt it. (2)

That is why the timing rules matter. Even when they are followed, only a small fraction of each tablet is absorbed, so tablet doses are measured in milligrams per day rather than fractions of a milligram per week.

Fig. 1 — The morning routine for the semaglutide tablet: empty stomach, up to 120 ml of water, wait 30 minutes.
Fig. 1 — The morning routine for the semaglutide tablet.
Fig. 2 — Semaglutide tablet doses stepped up from 3 mg to 7 mg to 14 mg a day.
Fig. 2 — Daily doses are stepped up over at least two months.

What the trials show on weight

Oral semaglutide has been studied at two very different strengths: the diabetes doses (up to 14 mg a day) in the PIONEER trials, and much higher doses made for weight management in the OASIS trials. (3) (4)

Trial

Population (n)

Dose and duration

Weight change

Placebo

PIONEER 1

703 · type 2 diabetes

14 mg a day, 26 weeks

-3.7 kg

-1.4 kg

OASIS 4

307 · obesity or overweight

25 mg a day, 64 weeks

-13.6%

-2.2%

PIONEER: the diabetes doses

In people with type 2 diabetes, the 14 mg tablet lowered HbA1c and led to modest weight loss, about 3 to 4 kg on average over six months. That is useful, but much less than with medicines designed for weight management. (3)

OASIS: higher doses for weight

When much higher daily doses were tested in people with obesity, weight loss was far larger: 13.6% with 25 mg over 64 weeks in OASIS 4, and 15.1% with 50 mg over 68 weeks in OASIS 1, compared with about 2% on placebo. (4) (6)

Fig. 3 — Average weight change with high-dose oral semaglutide versus placebo in OASIS 1 and OASIS 4.
Fig. 3 — Average change in body weight with high-dose oral semaglutide versus placebo. Source: OASIS 1 and OASIS 4 (4)(6).
What else changes on treatment?

Alongside weight, oral semaglutide was associated with improvements in:

  • HbA1c (average blood sugar)
  • Fasting blood glucose
  • Waist circumference
  • Body mass index (BMI)
  • Systolic blood pressure
  • Triglycerides

In people with type 2 diabetes and heart or kidney disease, a large outcome trial (SOUL) found that oral semaglutide reduced major cardiovascular events compared with placebo. (7)

Results depend heavily on taking the tablet correctly every morning. Missed or mistimed doses are one of the most common reasons the tablet seems not to work.

Who may be suitable?

Your doctor will look at your diagnosis, your BMI using Asian cut-offs, blood sugar, kidney function, other medicines, and whether a daily morning routine is realistic for you. People with a personal or family history of medullary thyroid cancer or MEN2 should not take semaglutide. (5) (8)

Tablet or weekly injection?

Both contain semaglutide, but they are different products with different registered uses in Singapore.

The weekly injection, up to 2.4 mg, is registered for chronic weight management. In the STEP 1 trial it produced average weight loss of about 15% over 68 weeks. (9)

The daily diabetes tablet, up to 14 mg, is registered for type 2 diabetes. Its effect on weight is smaller, and it needs the empty-stomach routine every morning.

Some people prefer a tablet to an injection; others prefer one dose a week with no daily rules. A doctor can help you decide which fits your health and your routine.

Fig. 4 — The semaglutide tablet versus the weekly semaglutide injection.
Fig. 4 — The semaglutide tablet versus the weekly injection.

Side effects and safety

在整个治疗过程中,医疗监督是必要的,以确保患者的安全和治疗的有效性。

Commonly reported effects

  • Nausea
  • Diarrhoea
  • Vomiting
  • Constipation
  • Stomach pain
  • Reduced appetite
预约咨询并检查您的资格
减肥有时会让人感到不知所措和充满挑战。然而,您不必独自面对。有了正确的治疗方案和专业的指导,您可以实现可持续的减肥,并自信地重获健康。

立即预约咨询,获取全面的身体分析和个性化治疗方案。
预约咨询
常见问题
参考文献

Studies and sources cited in this document

  1. U.S. Food and Drug Administration. FDA approves first oral GLP-1 treatment for type 2 diabetes. September 2019.
  2. Buckley ST, Bækdal TA, Vegge A, et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Sci Transl Med. 2018;10(467):eaar7047.
  3. Aroda VR, Rosenstock J, Terauchi Y, et al. PIONEER 1: Efficacy and Safety of Oral Semaglutide Monotherapy in Type 2 Diabetes. Diabetes Care. 2019;42(9):1724-1732.
  4. Wharton S, et al., for the OASIS 4 Investigators. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. N Engl J Med. 2025.
  5. Health Sciences Authority, Singapore. Register of Therapeutic Products: semaglutide. Checked November 2026.
  6. Knop FK, Aroda VR, do Vale RD, et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1). Lancet. 2023;402:705-719.
  7. McGuire DK, Marx N, Mulvagh SL, et al., for the SOUL Investigators. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. N Engl J Med. 2025.
  8. Health Promotion Board, Singapore. Body Mass Index (BMI) cut-off points for Asian adults.
  9. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384:989-1002.

Detect any underlying health conditions.

您上次进行全面体检是什么时候?掌控您的健康——从一次 全面全身健康检查 并咨询您的医生。

请说明您目前的问题,或分享任何其他需要在您预约前告知我们的备注。

今天就开始掌控您的健康。

您的提交已收到。
您的提交已收到。我们的客服代表将尽快与您联系!如需更快回复,请致电我们: +65 8129 8877
哎呀!提交表格时出错了。